Caribou Biosciences (NASDAQ:CRBU) Announces Quarterly Earnings Results

Caribou Biosciences (NASDAQ:CRBU) released its quarterly earnings results on Thursday. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02, FiscalAI reports. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. The business had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $1.60 million.

Caribou Biosciences Stock Performance

Shares of NASDAQ CRBU traded up $0.04 during mid-day trading on Friday, hitting $0.45. The stock had a trading volume of 1,699,805 shares, compared to its average volume of 6,005,073. The business has a 50 day moving average price of $0.95 and a two-hundred day moving average price of $1.60. Caribou Biosciences has a 1 year low of $0.40 and a 1 year high of $2.49. The firm has a market cap of $48.11 million, a P/E ratio of -0.44 and a beta of 2.50.

Analyst Ratings Changes

A number of equities analysts have recently commented on CRBU shares. Brookline Capital Markets lowered shares of Caribou Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 7th. Leerink Partners downgraded shares of Caribou Biosciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $4.00 to $1.00 in a report on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Thursday, October 15th. Royal Bank Of Canada lowered shares of Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 target price for the company. in a research report on Wednesday, October 7th. Finally, HC Wainwright cut Caribou Biosciences from a “buy” rating to a “neutral” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Caribou Biosciences currently has a consensus rating of “Hold” and an average target price of $4.50.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses CRISPR gene-editing technology to engineer allogeneic, or “off-the-shelf,” immune-cell therapies designed to target cancer cells while reducing limitations associated with individualized cell treatments.

Caribou’s research platform is based on CRISPR hybrid RNA-DNA guide technology, which is intended to support precise and efficient genome editing.